A Study to Evaluate the Efficacy and Safety of Apremilast in Patients of Chronic and Recurrent Erythema Nodosum Leprosum

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 15, 2019

Primary Completion Date

March 14, 2020

Study Completion Date

June 30, 2020

Conditions
Erythema Nodosum Leprosum
Interventions
DRUG

Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet

"The study patients will be treated with oral apremilast, administered initially a dose of 10 mg once daily, gradually increasing to reach the maximal therapeutic dosage of 30 mg twice daily before end of 1st week of starting the therapy.~The treatment will be continued till 6 months and we will taper the steroids by 10mg/ 2 weeks till 20mg and then 5 mg/ 2 weeks till discontinuation of steroids.~If a patient worsens after treatment or develops any serious adverse event after initiation of treatment, he will be withdrawn from the study.~If there is no response to the treatment and we are unable to taper steroids after 12 weeks of therapy then the patient will be withdrawn from the study"

Trial Locations (3)

160012

Dermatology OPD, New OPD Building, Level 5C, Postgraduate Institute of Medical Education and Research, Chandigarh

PGIMER, Chandigarh

Tarun Narang, Chandigarh

All Listed Sponsors
lead

Post Graduate Institute of Medical Education and Research, Chandigarh

OTHER

NCT04822909 - A Study to Evaluate the Efficacy and Safety of Apremilast in Patients of Chronic and Recurrent Erythema Nodosum Leprosum | Biotech Hunter | Biotech Hunter